NCT01153984View on ClinicalTrials.gov

A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Carcinoma，Non-Small-Cell Lung

Interventions

DRUG

Erlotinib

Erlotinib 150 mg oral doses will be administered daily.

Trial Locations (9)

6600

Uni Hospital St. Spiridon; Clinica Oncologie-Radiotherapie, Iași

300167

S.C. Life Search S.R.L; Medical Oncology Clinic, Timișoara

300239

ONCOMED - Medical Centre, Timișoara

400015

Oncology Inst. Cluj-Napoca; Cancer Dept, Cluj-Napoca

510073

County Hospital Alba; Oncology, Alba Iulia

022328

Institut of Oncology Al. Trestioreanu Bucharest; Oncology, Bucharest

022338

Institute Of Oncology Bucharest; Medical Oncology, Bucharest

04195

Spitalul de Boli Cronice Sf. Luca, Bucharest

050098

Emergency University Bucharest Hospital; Oncology Department, Bucharest

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01153984 - A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations | Biotech Hunter | Biotech Hunter